BioCentury | Aug 1, 2020
Emerging Company Profile

VIB spinout ExeVir targeting COVID-19 with single-domain antibody technology

...November. Mummenbrauer expects the series A round -- which saw participation from VIB, UCB Ventures, SFPI-FPIM...
...Number of employees: 3 Funds raised: €23 million ($26.9 million) Investors: Fund+, VIB, UCB Ventures, SFPI-FPIM...
...von Willebrand factor Danielle Golovin, Staff Writer Cablivi, anti-vWF Nanobody, caplacizumab (ALX-0081/ALX-0681) Flanders Institute for Biotechnology (VIB) UCB Ventures SFPI-FPIM V-Bio...
BioCentury | Feb 3, 2020
Deals

Catalent adds another foothold in new modality manufacturing via takeout of cell therapy provider MaSTherCell

...MaSTherCell’s investors include Great Point Partners, CDMO Orgenesis Inc. (NASDAQ:ORGS) and Belgian government investment company SFPI-FPIM...
BioCentury | Jan 23, 2020
Financial News

Jan. 22 Financial Quick Takes: Genmab-J&J, Adaptimmune, Revolution, PDC*line

...Partners, Shinhan-Cognitive Start-up Fund, UTC 2019 Bioventurefund, SRIW and Sambrinvest. Also participating were existing investors SFPI-FPIM...
BioCentury | May 24, 2019
Finance

How Europe’s hotspots of innovation could fuel its rise as a global player in new modalities

...repair Cancer iTeos Therapeutics S.A. $75.0 Series B HBM Partners, 6 Dimensions Capital, Curative Ventures, SFPI-FPIM...
BioCentury | Apr 3, 2017
Company News

Ogeda takeout gives Astellas hot flashes candidate

...S.A. until October 2016. Investors in its €18 million ($19.8 million) series B round included SFPI-FPIM...
BioCentury | Dec 2, 2016
Financial News

V-Bio closes EUR 76M fund

...million ($81 million). LPs include the European Investment Fund (EIF), PMV-ARKimedes, Korys, KU Leuven, Gimv, SFPI-FPIM...
BioCentury | Oct 26, 2016
Financial News

Fund+ closes EUR 125M fund

...EUR 125 million ($136.1 million), exceeding its EUR 100 million ($108.9 million) target. Investors included SFPI-FPIM...
BioCentury | May 19, 2016
Finance

Found in translation

...disorders Universite catholique de Louvain Gene/cell therapy; musculoskeletal Epimede; Fund+; Integrale; New Science Ventures; Nivelinvest; SFPI-FPIM...
BioCentury | Oct 12, 2015
Financial News

Euroscreen completes venture financing

...Belgium Business: Proteomics Date completed: 2015-10-02 Type: Venture financing Raised: EUR16 million ($18 million) Investors: SFPI-FPIM...
BioCentury | Oct 8, 2015
Financial News

Euroscreen raises EUR 16M in series B

...Brussels, Belgium) raised EUR 16 million in a series B round co-led by new investors SFPI-FPIM...
Items per page:
1 - 10 of 14
BioCentury | Aug 1, 2020
Emerging Company Profile

VIB spinout ExeVir targeting COVID-19 with single-domain antibody technology

...November. Mummenbrauer expects the series A round -- which saw participation from VIB, UCB Ventures, SFPI-FPIM...
...Number of employees: 3 Funds raised: €23 million ($26.9 million) Investors: Fund+, VIB, UCB Ventures, SFPI-FPIM...
...von Willebrand factor Danielle Golovin, Staff Writer Cablivi, anti-vWF Nanobody, caplacizumab (ALX-0081/ALX-0681) Flanders Institute for Biotechnology (VIB) UCB Ventures SFPI-FPIM V-Bio...
BioCentury | Feb 3, 2020
Deals

Catalent adds another foothold in new modality manufacturing via takeout of cell therapy provider MaSTherCell

...MaSTherCell’s investors include Great Point Partners, CDMO Orgenesis Inc. (NASDAQ:ORGS) and Belgian government investment company SFPI-FPIM...
BioCentury | Jan 23, 2020
Financial News

Jan. 22 Financial Quick Takes: Genmab-J&J, Adaptimmune, Revolution, PDC*line

...Partners, Shinhan-Cognitive Start-up Fund, UTC 2019 Bioventurefund, SRIW and Sambrinvest. Also participating were existing investors SFPI-FPIM...
BioCentury | May 24, 2019
Finance

How Europe’s hotspots of innovation could fuel its rise as a global player in new modalities

...repair Cancer iTeos Therapeutics S.A. $75.0 Series B HBM Partners, 6 Dimensions Capital, Curative Ventures, SFPI-FPIM...
BioCentury | Apr 3, 2017
Company News

Ogeda takeout gives Astellas hot flashes candidate

...S.A. until October 2016. Investors in its €18 million ($19.8 million) series B round included SFPI-FPIM...
BioCentury | Dec 2, 2016
Financial News

V-Bio closes EUR 76M fund

...million ($81 million). LPs include the European Investment Fund (EIF), PMV-ARKimedes, Korys, KU Leuven, Gimv, SFPI-FPIM...
BioCentury | Oct 26, 2016
Financial News

Fund+ closes EUR 125M fund

...EUR 125 million ($136.1 million), exceeding its EUR 100 million ($108.9 million) target. Investors included SFPI-FPIM...
BioCentury | May 19, 2016
Finance

Found in translation

...disorders Universite catholique de Louvain Gene/cell therapy; musculoskeletal Epimede; Fund+; Integrale; New Science Ventures; Nivelinvest; SFPI-FPIM...
BioCentury | Oct 12, 2015
Financial News

Euroscreen completes venture financing

...Belgium Business: Proteomics Date completed: 2015-10-02 Type: Venture financing Raised: EUR16 million ($18 million) Investors: SFPI-FPIM...
BioCentury | Oct 8, 2015
Financial News

Euroscreen raises EUR 16M in series B

...Brussels, Belgium) raised EUR 16 million in a series B round co-led by new investors SFPI-FPIM...
Items per page:
1 - 10 of 14